Ghrelin's Cardioprotective Effects: The Research
Ghrelin
+25% cardiac index
A single ghrelin infusion increased cardiac output by 25% and stroke volume by 30% in heart failure patients, while lowering blood pressure by 9 mmHg.
Nagaya et al., J Clin Endocrinol Metab, 2001
Nagaya et al., J Clin Endocrinol Metab, 2001
View as imageA peptide best known for making you hungry turns out to have a second life in cardiovascular research. Since its discovery in 1999, ghrelin has accumulated a body of evidence suggesting it protects cardiac tissue through mechanisms that operate independently of its growth hormone-releasing activity.[1] A 2021 review catalogued ghrelin's cardiovascular effects spanning anti-inflammation, anti-apoptosis, sympathetic modulation, autophagy regulation, and endothelial protection.[10] For a broader look at this peptide's biology and metabolic roles, see our complete guide to ghrelin. This article focuses on what the research shows about ghrelin's effects on the heart and blood vessels.
Key Takeaways
- Ghrelin infusion increased cardiac index by 25% and stroke volume by 30% in 12 heart failure patients (Nagaya et al., 2001)
- Three weeks of ghrelin therapy raised left ventricular ejection fraction from 27% to 31% in CHF patients (Nagaya et al., 2004)
- Ghrelin administration during reperfusion reduced myocardial LDH and myoglobin release in isolated rat hearts (Chang et al., 2004)
- Ghrelin-treated mice with dilated cardiomyopathy had prolonged survival compared to controls (Du et al., 2014)
- Ghrelin's cardiac receptor binding capacity increases during ischemia/reperfusion, suggesting an endogenous protective response (Chang et al., 2004)
- Plasma norepinephrine dropped from 1,132 to 655 pg/mL after three weeks of ghrelin in CHF patients (Nagaya et al., 2004)
How a Stomach Peptide Ended Up in Heart Research
Masayasu Kojima and colleagues isolated ghrelin from rat stomach tissue in 1999, identifying it as a 28-amino-acid peptide with an unusual octanoyl modification on its third serine residue.[2] The initial focus was on appetite and growth hormone release. The cardiovascular connection emerged when researchers found that the growth hormone secretagogue receptor (GHS-R1a), ghrelin's primary target, is expressed throughout the heart and vasculature.[1]
That receptor distribution was the first clue. If ghrelin receptors are present in ventricular tissue, coronary vasculature, and endothelial cells, the peptide is likely doing something there beyond stimulating hunger. The question became: what?
Acute Hemodynamic Effects in Heart Failure Patients
The first human cardiac data came from Nagaya and colleagues in 2001. In a placebo-controlled study of 12 patients with chronic heart failure, intravenous ghrelin infusion (0.1 mcg/kg/min) produced immediate hemodynamic improvements: mean arterial pressure decreased by 9 mmHg, cardiac index increased by 25%, and stroke volume index increased by 30%.[4] Heart rate did not change significantly, meaning the cardiac output increase came from improved stroke volume rather than tachycardia. Pulmonary pressures also remained stable.
These acute effects are noteworthy because they suggest ghrelin reduces afterload (the resistance the heart pumps against) while simultaneously improving contractility. That combination is rare in cardiovascular pharmacology. Most vasodilators reduce afterload but do not directly enhance contractile function. Notably, GLP-1 receptor agonists also demonstrate cardiovascular benefits, but through different mechanisms focused on metabolic and anti-atherosclerotic pathways rather than direct hemodynamic improvement.
Chronic Ghrelin Therapy: The Three-Week Clinical Trial
The same research group followed up with a longer trial. Ten patients with chronic heart failure received intravenous ghrelin (2 mcg/kg twice daily) for three weeks.[5] The results showed:
- Left ventricular ejection fraction increased from 27% to 31%
- Peak workload during exercise testing improved
- Peak oxygen consumption during exercise increased
- Lean body mass increased
- Muscle strength improved
- Plasma norepinephrine decreased from 1,132 to 655 pg/mL
That norepinephrine reduction is particularly significant. Elevated sympathetic nervous system activity is a hallmark of heart failure and drives disease progression. The 42% reduction in circulating norepinephrine suggests ghrelin directly modulates the autonomic nervous system, shifting the balance away from the harmful sympathetic overdrive that characterizes advanced heart failure.
Eight control patients who did not receive ghrelin showed no changes in any of these parameters over the same period.
The trial was small and unblinded, limiting the strength of these conclusions. But the magnitude of the effects, particularly the sympathetic suppression, generated significant interest in ghrelin as a cardiac therapeutic.
Protection Against Ischemia-Reperfusion Injury
When blood flow to the heart is interrupted (ischemia) and then restored (reperfusion), a paradoxical wave of damage occurs. This ischemia-reperfusion (I/R) injury is a major contributor to heart attack damage and a target for cardioprotective strategies.
Chang and colleagues demonstrated in 2004 that ghrelin administration during reperfusion directly protects the isolated rat heart.[6] Ghrelin at concentrations of 100 to 10,000 pM improved coronary flow, heart rate, left ventricular systolic pressure, and left ventricular end-diastolic pressure after ischemia. It also reduced the release of lactate dehydrogenase and myoglobin, enzymes that leak from damaged heart cells, indicating less cardiomyocyte injury.
A critical finding from this study: ghrelin's maximum binding capacity to cardiac sarcolemmal membranes increased after ischemia and increased further after reperfusion. The affinity of ghrelin for its receptor did not change, but the number of available binding sites went up. This suggests the heart upregulates ghrelin receptors during injury, as if calling for help from a protective signal it already knows how to use.
The protective effects were independent of growth hormone release, since the experiments used isolated hearts without pituitary tissue present.
The Endoplasmic Reticulum Stress Pathway
Zhang and colleagues identified one specific mechanism in 2009.[7] During ischemia-reperfusion, cardiac cells experience endoplasmic reticulum stress (ERS), a condition where the protein-folding machinery becomes overwhelmed. ERS activates cell death pathways through markers like GRP78, CHOP, and caspase-12.
Ghrelin pretreatment (10^-8 mol/kg, administered intraperitoneally twice before the experiment) significantly reduced all three ERS markers in rat hearts subjected to I/R injury. The downstream result: fewer apoptotic cardiomyocytes and better-preserved cardiac function. The effect was confirmed both in the intact Langendorff heart model and in isolated cardiac tissue treated with chemical ERS inducers.
This matters because ERS-driven cell death is not unique to ischemia-reperfusion. It contributes to cardiac damage in heart failure, diabetic cardiomyopathy, and other chronic conditions. A peptide that suppresses this pathway could have broad cardioprotective applications.
Anti-Inflammatory Mechanisms in Cardiac Surgery
Cardiopulmonary bypass (CPB) during heart surgery triggers a systemic inflammatory response that can damage the myocardium. Cao and colleagues tested whether ghrelin could mitigate this injury in a rat CPB model.[8]
Ghrelin reduced TNF-alpha and IL-6 levels, decreased myocardial myeloperoxidase activity (a marker of inflammatory cell infiltration), and reduced apoptosis and oxidative stress after CPB. Cardiac function improved in the ghrelin-treated group.
The mechanism involves the PI3K/Akt signaling pathway. When researchers blocked this pathway with wortmannin, or blocked the ghrelin receptor (GHS-R1a) with [D-Lys3]-GHRP-6, the cardioprotective effects disappeared. This confirmed that ghrelin's anti-inflammatory cardiac effects operate through a specific receptor-mediated signaling cascade, not a nonspecific pharmacological action.
In cultured cardiomyocytes subjected to simulated CPB conditions, ghrelin increased cell viability and reduced apoptosis through the same pathway, confirming the direct cellular mechanism.
Survival Benefit in Heart Failure Models
The most clinically relevant preclinical finding came from Du and colleagues in 2014.[9] Using a mouse model of inherited dilated cardiomyopathy (caused by a specific troponin T mutation), they administered ghrelin (150 mcg/kg subcutaneously, once daily) starting at 30 days of age and tracked survival over 30 days.
Ghrelin-treated mice lived significantly longer than saline-treated controls. Echocardiography showed ghrelin reduced left ventricular end-diastolic dimensions and increased ejection fraction. Histological analysis revealed less cardiac remodeling and fibrosis. Brain natriuretic peptide expression, a marker of cardiac stress, was markedly decreased.
Telemetry and heart rate variability analysis revealed the autonomic mechanism: ghrelin suppressed excessive cardiac sympathetic nerve activity and restored parasympathetic tone. This autonomic rebalancing aligns with the norepinephrine reduction seen in Nagaya's human studies and may be central to ghrelin's cardiac benefits.
The Autonomic Connection
The sympathetic nervous system data from multiple studies converges on a consistent picture. In heart failure, chronic sympathetic activation drives a vicious cycle: elevated catecholamines increase heart rate and contractile demand, promote arrhythmias, and accelerate remodeling. Beta-blockers, which suppress this cycle, are a cornerstone of heart failure therapy.
Ghrelin appears to achieve something similar through a different mechanism. The Nagaya 2004 clinical data showed a 42% reduction in plasma norepinephrine.[5] The Du 2014 telemetry data showed direct suppression of cardiac sympathetic nerve activity with recovery of parasympathetic function.[9] The Yuan 2021 review confirmed that autonomic modulation is considered one of ghrelin's primary cardiovascular protective mechanisms.[10]
Whether this autonomic effect is mediated centrally (through ghrelin receptors in the brainstem and hypothalamus) or peripherally (through vagal afferents in the gut) remains an open question. Both routes are plausible given ghrelin's receptor distribution.
Cardiac Cachexia: Where Heart Failure Meets Metabolism
Cardiac cachexia, the severe weight and muscle loss that accompanies advanced heart failure, dramatically worsens prognosis. Patients who develop cachexia have markedly higher mortality than those with equivalent cardiac dysfunction but preserved body mass. Ghrelin's unique position as both a cardiac-active and metabolic peptide makes it a natural candidate for this condition.[3] The peptide's appetite-stimulating and anabolic properties, normally discussed in the context of ghrelin's role in hunger and reward signaling, become therapeutically relevant when the problem is wasting rather than excess. For a dedicated look at ghrelin's therapeutic potential in wasting diseases, see our article on ghrelin for cachexia.
Nagaya's rat studies demonstrated that chronic ghrelin administration attenuated the development of cardiac cachexia after coronary artery ligation.[11] CHF rats treated with ghrelin gained 10% body weight compared to 3% in controls, while simultaneously showing improved cardiac output (315 vs. 266 mL/min/kg) and higher LV dP/dt max (5,738 vs. 4,363 mmHg/s). The 2004 human study confirmed that ghrelin increased lean body mass and muscle strength in CHF patients, supporting translation from the animal model to clinical relevance.[5]
This dual cardiac-metabolic benefit sets ghrelin apart from other cardioprotective strategies. No other single agent simultaneously improves ventricular function, reduces sympathetic drive, and reverses the muscle wasting that accelerates decline in severe heart failure. This connection to appetite and metabolism is explored in depth in our article on how ghrelin stimulates growth hormone and appetite simultaneously.
Limitations and Open Questions
The clinical evidence for ghrelin's cardioprotective effects remains preliminary. Key limitations include:
Small sample sizes. The largest human study involved only 12 patients. No large randomized controlled trial has been conducted. The effect sizes are impressive, but they come from studies that lack statistical power and rigorous blinding.
Short duration. The longest clinical exposure was three weeks. Heart failure is a chronic condition. Whether ghrelin's benefits persist, plateau, or reverse with longer administration is unknown.
Animal-to-human translation gaps. The ischemia-reperfusion, ERS, and survival data come entirely from rodent models. These mechanisms are plausible in humans, but direct evidence is lacking.
Delivery challenges. Ghrelin is a peptide with a short half-life requiring intravenous administration in the clinical studies. Practical long-term therapy would require ghrelin analogs or alternative delivery methods.
Appetite effects. Ghrelin's hunger-stimulating properties, beneficial in cachexia, could be problematic in heart failure patients without wasting. Weight gain from increased appetite rather than lean mass accretion could worsen outcomes.
Receptor complexity. Ghrelin's cardiovascular effects involve GHS-R1a and potentially other receptor pathways. The full signaling landscape is not mapped, complicating drug development. For more on how ghrelin resistance complicates receptor-targeted approaches, see the dedicated article in this cluster.
The Lilleness 2016 review in Cardiology in Review concluded that while ghrelin's cardiovascular effects are robust in preclinical settings, the clinical significance remains to be established through larger, longer, and better-designed trials.[1]
The Bottom Line
Ghrelin demonstrates consistent cardioprotective effects across preclinical models, including protection against ischemia-reperfusion injury, suppression of inflammatory and apoptotic pathways, and autonomic rebalancing. Small human studies show acute hemodynamic benefits and improvements in cardiac function, exercise capacity, and muscle wasting over three weeks. The evidence is promising but limited by small sample sizes, short durations, and the absence of large randomized trials.